全文获取类型
收费全文 | 500篇 |
免费 | 15篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 13篇 |
基础医学 | 112篇 |
口腔科学 | 12篇 |
临床医学 | 105篇 |
内科学 | 84篇 |
皮肤病学 | 3篇 |
神经病学 | 24篇 |
特种医学 | 28篇 |
外科学 | 42篇 |
预防医学 | 26篇 |
眼科学 | 6篇 |
药学 | 30篇 |
中国医学 | 9篇 |
肿瘤学 | 18篇 |
出版年
2023年 | 3篇 |
2021年 | 4篇 |
2020年 | 8篇 |
2018年 | 7篇 |
2017年 | 5篇 |
2016年 | 17篇 |
2015年 | 13篇 |
2014年 | 9篇 |
2013年 | 10篇 |
2012年 | 8篇 |
2011年 | 21篇 |
2010年 | 11篇 |
2009年 | 11篇 |
2008年 | 20篇 |
2007年 | 14篇 |
2006年 | 11篇 |
2005年 | 21篇 |
2004年 | 10篇 |
2003年 | 16篇 |
2002年 | 15篇 |
2001年 | 9篇 |
2000年 | 15篇 |
1999年 | 14篇 |
1997年 | 3篇 |
1993年 | 4篇 |
1992年 | 17篇 |
1991年 | 19篇 |
1990年 | 18篇 |
1989年 | 16篇 |
1988年 | 12篇 |
1987年 | 17篇 |
1986年 | 9篇 |
1985年 | 10篇 |
1983年 | 4篇 |
1982年 | 2篇 |
1979年 | 7篇 |
1978年 | 4篇 |
1977年 | 4篇 |
1976年 | 6篇 |
1975年 | 4篇 |
1974年 | 5篇 |
1973年 | 10篇 |
1972年 | 8篇 |
1971年 | 6篇 |
1970年 | 9篇 |
1969年 | 8篇 |
1968年 | 4篇 |
1967年 | 11篇 |
1966年 | 11篇 |
1965年 | 3篇 |
排序方式: 共有517条查询结果,搜索用时 78 毫秒
1.
Sergey Kalinin Gordon P. Meares Shao Xia Lin Elizabeth A. Pietruczyk Gesine Saher Lena Spieth Klaus-Armin Nave Anne I. Boullerne Sarah E. Lutz Etty N. Benveniste Douglas L. Feinstein 《Glia》2020,68(3):600-616
Liver kinase B1 (LKB1) is a ubiquitously expressed kinase involved in the regulation of cell metabolism, growth, and inflammatory activation. We previously reported that a single nucleotide polymorphism in the gene encoding LKB1 is a risk factor for multiple sclerosis (MS). Since astrocyte activation and metabolic function have important roles in regulating neuroinflammation and neuropathology, we examined the serine/threonine kinase LKB1 in astrocytes in a chronic experimental autoimmune encephalomyelitis mouse model of MS. To reduce LKB1, a heterozygous astrocyte-selective conditional knockout (het-cKO) model was used. While disease incidence was similar, disease severity was worsened in het-cKO mice. RNAseq analysis identified Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enriched in het-cKO mice relating to mitochondrial function, confirmed by alterations in mitochondrial complex proteins and reductions in mRNAs related to astrocyte metabolism. Enriched pathways included major histocompatibility class II genes, confirmed by increases in MHCII protein in spinal cord and cerebellum of het-cKO mice. We observed increased numbers of CD4+ Th17 cells and increased neuronal damage in spinal cords of het-cKO mice, associated with reduced expression of choline acetyltransferase, accumulation of immunoglobulin-γ, and reduced expression of factors involved in motor neuron survival. In vitro, LKB1-deficient astrocytes showed reduced metabolic function and increased inflammatory activation. These data suggest that metabolic dysfunction in astrocytes, in this case due to LKB1 deficiency, can exacerbate demyelinating disease by loss of metabolic support and increase in the inflammatory environment. 相似文献
2.
3.
Egor V. Kalinin Yaroslava M. Chalenko Elena V. Sysolyatina Konstantin Y. Midiber Alexey M. Gusarov Olga I. Kechko Alexandra A. Kulikova Ludmila M. Mikhaleva Andrey Ya. Mukhachev Yaroslav M. Stanishevskyi Vladimir A. Mitkevich Konstantin A. Sobyanin Svetlana A. Ermolaeva 《Drug development research》2021,82(1):123-132
Hepatocyte growth factor (HGF) is central to liver regeneration. The Internalin B (InlB) protein is a virulence factor produced by the pathogenic bacterium Listeria monocytogenes. InlB is known to mimic HGF activity by interacting with the HGF receptor (HGFR) and activating HGFR‐controlled signaling pathways. We expressed and purified the HGFR‐binding InlB domain, InlB321/15, cloned from the fully virulent clinical L. monocytogenes strain. HGFR and Erk1/2 phosphorylation was determined using Western blotting. The capacity of InlB321/15 to bind HGFR was measured using microscale thermophoresis. Liver regeneration was studied in a model of 70% partial hepatectomy (70%PHx) in male Wistar rats. The nuclear grade parameters were quantified using manual (percentage of binuclear hepatocytes), automated (nuclear diameters), or combined (Ki67 proliferation index) scoring methods. Purified InlB321/15 stimulated HGFR and Erk1/2 phosphorylation and accelerated the proliferation of HepG2 cells. InlB321/15 bound HGFR with Kd = 7.4 ± 1.3 nM. InlB321/15 injected intravenously on the second, fourth, and sixth days after surgery recovered the liver mass and improved the nuclear grade parameters. Seven days post 70% PHx, the liver weight indexes were 2.9 and 2.0%, the hepatocyte proliferation indexes were 19.8 and 0.6%, and the percentages of binucleated hepatocytes were 6.7 and 4.0%, in the InlB321/15‐treated and control animals, respectively. Obtained data demonstrated that InlB321/15 improved hepatocyte proliferation and stimulated liver regeneration in animals with 70% hepatectomy. 相似文献
4.
John L. Butler VI MS 《Journal of family psychotherapy》2013,24(1):87-88
No abstract available for this article. 相似文献
5.
6.
Whelton A Fort JG Puma JA Normandin D Bello AE Verburg KM;SUCCESS VI Study Group 《American journal of therapeutics》2001,8(2):85-95
BACKGROUND: Arthritis and hypertension are common comorbid conditions affecting elderly adults. Use of nonsteroidal anti-inflammatory drugs in patients treated with antihypertensive medication can lead to destabilization of blood pressure control and other cardiorenal events. The potential for similar interactions with cyclooxygenase-2-specific inhibitors has not been fully explored. The authors evaluated the cardiorenal safety of two new cyclooxygenase-2-specific inhibitors, celecoxib and rofecoxib.METHODS: This study was a 6-week, randomized, parallel-group, double-blind trial in patients with osteoarthritis who were > or =65 years of age and were taking antihypertensive agents. Patients received once-daily celecoxib 200 mg or rofecoxib 25 mg. The primary endpoints were the development of edema, changes in systolic blood pressure, and changes in diastolic blood pressure as measured at any time point in the study. Measurements occurred at baseline and after 1, 2, and 6 weeks of treatment. FINDINGS: Eight hundred ten patients received study medication (celecoxib, n = 411; rofecoxib, n = 399). Nearly twice as many rofecoxib- compared with celecoxib-treated patients experienced edema (9.5% vs. 4.9%, P = 0.014). Systolic blood pressure increased significantly in 17% of rofecoxib- compared with 11% of celecoxib-treated patients (P = 0.032) at any study time point. Diastolic blood pressure increased in 2.3% of rofecoxib- compared with 1.5% of celecoxib-treated patients (P = 0.44). At week 6, the change from baseline in mean systolic blood pressure was +2.6 mmHg for rofecoxib compared with -0.5 mmHg for celecoxib (P = 0.007). CONCLUSIONS: Patients taking antihypertensive therapy and receiving cyclooxygenase-2-specific inhibitors should be monitored for the development of cardiorenal events. Patients receiving celecoxib experienced less edema and less destabilization of blood pressure control compared with those receiving rofecoxib. 相似文献
7.
8.
9.
10.
The review presents current data on production, release and reception of natriuretic peptides (NUP) with special focus on NUP effects on blood circulation, urination in arterial hypertension and cardiac failure; analyses interaction between NUP and renin-angiotensin-aldosterone system, effects of new drugs influencing these systems. 相似文献